In MG populations, one OS publication reported a statistically significant decline in eGFR following 80 months of mixed ERT (26 patients) [108], and another OS noted no statistically significant change in eGFR for patients treated with agalsidase alfa 0.2 mg/kg EOW or agalsidase beta 0.2 mg/kg EOW combined [180]. The gene discussed is GLA; the disease is myasthenia gravis.